Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joon Byun

Showing results (11-20 of 40) with videos related to

Pageof 4
Sort By:
Investigative and Clinical Urology|March 17, 2016
Value of urinary topoisomerase-IIA cell-free DNA for diagnosis of bladder cancerYe-Hwan Kim, Chunri Yan, Il-Seok Lee, et al.
Investigative and Clinical Urology|May 2, 2025
Optimizing extraction of microbial DNA from urine: Advancing urinary microbiome research in bladder cancerChuang-Ming Zheng, Ho Won Kang, Seongmin Moon, et al.
Prostate International|February 14, 2022
Expression of hsv1-miR-H18 and hsv2-miR-H9 as a field defect marker for detecting prostate cancerYoung Joon Byun, Ho Won Kang, Xuan-Mei Piao, et al.
Oncology Letters|November 8, 2024
Single‑center, retrospective, evaluator‑blinded, pilot and pivotal clinical trials: Assessing the mirCaP Kit (hsv2‑miR‑H9/hsa‑miR‑3659) as a diagnostic marker for prostate cancer in patients with PSA levels in the gray zoneWon Tae Kim, Kyeong Kim, Ho Won Kang, et al.
Investigative and Clinical Urology|July 16, 2020
A novel urinary mRNA signature using the droplet digital polymerase chain reaction platform improves discrimination between prostate cancer and benign prostatic hyperplasia within the prostate-specific antigen gray zoneHo Won Kang, Hee Youn Lee, Young Joon Byun, et al.
Journal of Korean Medical Science|November 20, 2018
<i>CDC6</i> mRNA Expression Is Associated with the Aggressiveness of Prostate CancerYe-Hwan Kim, Young Joon Byun, Won Tae Kim, et al.
Investigative and Clinical Urology|January 10, 2024
<i>COL6A1</i> expression as a potential prognostic biomarker for risk stratification of T1 high grade bladder cancer: Unveiling the aggressive nature of a distinct non-muscle invasive subtypeKyeong Kim, Young Joon Byun, Chuang-Ming Zheng, et al.
International Journal of Molecular Sciences|December 10, 2021
Prognostic Value of BUB1 for Predicting Non-Muscle-Invasive Bladder Cancer ProgressionXuan-Mei Piao, Chaelin You, Young Joon Byun, et al.
International Journal of Molecular Sciences|October 26, 2024
Differential Urinary Microbiome and Its Metabolic Footprint in Bladder Cancer Patients Following BCG TreatmentKyungchan Min, Chuang-Ming Zheng, Sujeong Kim, et al.
International Journal of Molecular Sciences|November 26, 2022
Utility of a Molecular Signature for Predicting Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer Patients: Comparison with the EORTC, CUETO and 2021 EAU Risk GroupsXuan-Mei Piao, Seon-Kyu Kim, Young Joon Byun, et al.
Pageof 4

Showing results (11-20 of 40) with videos related to

Sort By:
Pageof 4
Investigative and Clinical Urology|March 17, 2016
Value of urinary topoisomerase-IIA cell-free DNA for diagnosis of bladder cancerYe-Hwan Kim, Chunri Yan, Il-Seok Lee, et al.
Investigative and Clinical Urology|May 2, 2025
Optimizing extraction of microbial DNA from urine: Advancing urinary microbiome research in bladder cancerChuang-Ming Zheng, Ho Won Kang, Seongmin Moon, et al.
Prostate International|February 14, 2022
Expression of hsv1-miR-H18 and hsv2-miR-H9 as a field defect marker for detecting prostate cancerYoung Joon Byun, Ho Won Kang, Xuan-Mei Piao, et al.
Oncology Letters|November 8, 2024
Single‑center, retrospective, evaluator‑blinded, pilot and pivotal clinical trials: Assessing the mirCaP Kit (hsv2‑miR‑H9/hsa‑miR‑3659) as a diagnostic marker for prostate cancer in patients with PSA levels in the gray zoneWon Tae Kim, Kyeong Kim, Ho Won Kang, et al.
Investigative and Clinical Urology|July 16, 2020
A novel urinary mRNA signature using the droplet digital polymerase chain reaction platform improves discrimination between prostate cancer and benign prostatic hyperplasia within the prostate-specific antigen gray zoneHo Won Kang, Hee Youn Lee, Young Joon Byun, et al.
Journal of Korean Medical Science|November 20, 2018
<i>CDC6</i> mRNA Expression Is Associated with the Aggressiveness of Prostate CancerYe-Hwan Kim, Young Joon Byun, Won Tae Kim, et al.
Investigative and Clinical Urology|January 10, 2024
<i>COL6A1</i> expression as a potential prognostic biomarker for risk stratification of T1 high grade bladder cancer: Unveiling the aggressive nature of a distinct non-muscle invasive subtypeKyeong Kim, Young Joon Byun, Chuang-Ming Zheng, et al.
International Journal of Molecular Sciences|December 10, 2021
Prognostic Value of BUB1 for Predicting Non-Muscle-Invasive Bladder Cancer ProgressionXuan-Mei Piao, Chaelin You, Young Joon Byun, et al.
International Journal of Molecular Sciences|October 26, 2024
Differential Urinary Microbiome and Its Metabolic Footprint in Bladder Cancer Patients Following BCG TreatmentKyungchan Min, Chuang-Ming Zheng, Sujeong Kim, et al.
International Journal of Molecular Sciences|November 26, 2022
Utility of a Molecular Signature for Predicting Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer Patients: Comparison with the EORTC, CUETO and 2021 EAU Risk GroupsXuan-Mei Piao, Seon-Kyu Kim, Young Joon Byun, et al.
Pageof 4